WW’s Clinical Subscriber Growth and Marketing Spend Shifts Contradict Earlier 2026 Outlook

<<>>

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $162.3 million, compared to $189.2 million in the second quarter of 2025
• Gross Margin: 70.3%, adjusted gross margin was 73.6%, both on par with Q1 and near record highs
• Operating Margin: 24.5% adjusted EBITDA margin, compared with a loss of $1.8 million in Q1 2026

Guidance:

• Reaffirm full-year 2026 revenue guidance of $620M to $635M and adjusted EBITDA guidance of $105M to $115M.
• Expect clinical subscription revenue to represent 25% to 30% of 2026 total revenue, up from 15.9% in 2025.
• Expect continued year-over-year growth in Core Plus subscribers and moderation in behavioral subscriber declines.
• Expect modest adjusted growth margin decline to above 17% and marketing spend below first-half levels as a percentage of revenue.
• Expect positive operating cash flow, ~$45M-$50M interest costs, and cash taxes of $5M-$10M for full year 2026.

Business Commentary:

Subscriber Trends and Program Mix:

• Weight Watchers reported total end-of-period subscribers of 2.5 million. The Core Plus tier grew to 541,000 subscribers, an increase of 13.9% year-over-year, marking the third consecutive quarter of sequential growth.
• The decline in total behavioral subscribers was concentrated in the Core tier, with Core Plus showing growth. This trend reflects a shift towards higher-value membership tiers.

Clinical Subscription Growth:

• The company's clinical subscribers reached 197,000, up 55.7% year-over-year, indicating strong growth in the clinical segment.
• The increase is attributed to strategic initiatives such as partnerships with Sam's Club and the Medicare GLP-1 Bridge Program, which enhance medication access and support.

Financial Performance and Margin Stability:

• Weight Watchers reported revenue of $162.3 million for Q2 2026, with an adjusted gross margin of 73.6%, consistent with Q1 levels.
• Despite a revenue decline and a shift towards higher-cost clinical services, the company maintained stable margins through structural work and operational efficiency improvements.

Marketing and Cash Flow Strategy:

• Marketing expenses were $47.9 million, or 29.5% of revenue, reflecting an intentional recalibration following a reduction during the Chapter 11 reorganization.
• The company generated approximately $24.3 million in operating cash flow, which was used to pay down debt, reducing the term loan balance by more than 70%.

Outlook and Strategic Focus:

• Weight Watchers reaffirmed its full-year 2026 guidance for revenue of $620 million to $635 million and adjusted EBITDA of $105 million to $115 million.
• The company plans to continue investing in strategic priorities, including clinical and behavioral offerings, to support long-term growth and transformation.

Sentiment Analysis:

Overall Tone: Positive

• "Our financial footing continues to improve... These results demonstrate the earnings power of our more disciplined operating model." "We are reaffirming our full-year guidance..." "We are seeing clear signs of progress..." "We see a company built on a stronger financial foundation..." "...we head into the second half with confidence."

Contradiction Point 1

Clinical Subscriber Growth Expectations

Contradiction in the expected year-over-year growth rate for Clinical subscribers.

What was the summary of the 2026 Q2 earnings call? - Summary of 2026Q2 Earnings Call

2026Q2: Clinical subscribers grew 55.7% YoY in Q2... Clinical subscription revenue is expected to represent 25% to 30% of total 2026 revenue. - Felicia Della Fortuna(CFO)

How have subscriber and revenue growth trends been for the Clinical segment? - Nathaniel Feather (Morgan Stanley)

2026Q1: Clinical subscribers ended Q1 at 197,000, up 51% sequentially. Sequential growth in Clinical subscribers for the rest of the year will be significantly muted compared to Q4 2025 to Q1 2026. - Felicia Della Fortuna(CFO)

Contradiction Point 2

Clinical Subscription Revenue Growth and Subscriber Growth Correlation

Contradiction in the relationship between Clinical revenue and subscriber growth, specifically regarding the ease of lapping comparisons.

Summary of 2026Q2 Earnings Call - Summary of 2026Q2 Earnings Call

2026Q2: Clinical subscription revenue grew to $39.9 million, up from $30.6 million in Q2 2025... Clinical subscription revenue is expected to represent 25% to 30% of total 2026 revenue. - Felicia Della Fortuna(CFO)

What is the expected contribution of Clinical revenue to total revenue? - Alex Fuhrman (Lucid Capital Markets)

2026Q1: Revenue from Clinical will lap easier comparisons in Q3 and Q4 2026. - Felicia Della Fortuna(CFO)

Contradiction Point 3

Marketing Spend Allocation

Contradiction on the level of marketing spend in Q2 2026 compared to Q1 2026.

N/A - N/A

2026Q2: Marketing Expense: $47.9 million (29.5% of revenue), a deliberate pullback from the peak season spending in Q1 2026 and significantly lower than the $92.9 million in Q1 2026. - Felicia Della Fortuna(CFO)

Summary of financial performance. - Justin Ages (CJS Securities)

20260316-2025 Q4: The Q1 marketing spend was focused on a full-funnel strategy across television and out-of-home to expand overall reach... - Felicia DellaFortuna(CFO)

Contradiction Point 4

Financial Performance Expectations

2026Q2 guidance indicates a significant revenue decline, while 2025Q3 expressed confidence in the clinic business trough.

(Not specified in provided text) - (Not specified in provided text)

2026Q2: Reaffirmed 2026 guidance of $620 million to $635 million in revenue. - Felicia Della Fortuna(CFO)

What is the guidance for 2026Q2 in the 'Outlook & Guidance' section? - Alex Fuhrman (Lucid Capital Markets, LLC)

2025Q3: Q3 2025 is expected to be the trough for end-of-period clinic subscribers. - Tara Comonte(CEO) & Jon Volkmann(COO) & Felicia DellaFortuna(CFO)

Contradiction Point 5

Marketing Spend Allocation

2026Q2 describes a deliberate marketing spend pullback, contradicting 2025Q3's focus on a new, brand-driven marketing strategy.

(Not specified in provided text) - (Not specified in provided text)

2026Q2: Marketing Expense was $47.9 million (29.5% of revenue), a deliberate pullback from the peak season spending in Q1 2026. - Felicia Della Fortuna(CFO)

What are the marketing expense details for 2026Q2 as outlined in the Financial Summary section? - Justin Ages (CJS Securities, Inc.)

2025Q3: The company is shifting its marketing strategy from heavy discounting... to a more full-funnel approach leveraging the brand’s authority... - Tara Comonte(CEO)

<<>>